Bedaquiline - CAS 843663-66-1
Catalog number: B0084-152490
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C32H31BrN2O2
Molecular Weight:
555.5
COA:
Inquire
Targets:
Antibacterial
Description:
TMC207 is a first-in-class diarylquinoline compound with a novel mechanism of action, the inhibition of bacterial ATP synthase, and potent activity against drug-sensitive and drug-resistant TB.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-152490 100 mg $198 In stock
Bulk Inquiry
Purity:
0.97
Synonyms:
Sirturo; TMC207; TMC-207; TMC 207; R207910; R-207910; R 207910.
MSDS:
Inquire
InChIKey:
QUIJNHUBAXPXFS-UHFFFAOYSA-N
InChI:
InChI=1S/C32H31BrN2O2/c1-35(2)19-18-32(36,28-15-9-13-22-10-7-8-14-26(22)28)30(23-11-5-4-6-12-23)27-21-24-20-25(33)16-17-29(24)34-31(27)37-3/h4-17,20-21,30,36H,18-19H2,1-3H3
Canonical SMILES:
CN(C)CCC(C1=CC=CC2=CC=CC=C21)(C(C3=CC=CC=C3)C4=C(N=C5C=CC(=CC5=C4)Br)OC)O
1.Global Introduction of New Multidrug-Resistant Tuberculosis Drugs-Balancing Regulation with Urgent Patient Needs.
Sullivan T, Ben Amor Y. Emerg Infect Dis. 2016 Mar;22(3). doi: 10.3201/eid2203.151228.
New treatments for multidrug-resistant tuberculosis (MDR TB) are urgently needed. Two new drugs, bedaquiline and delamanid, have recently been released, and several new drugs and treatment regimens are in the pipeline. Misuse of TB drugs is a principal cause of drug resistance. As new drugs and regimens reach the market, the need to make them available to patients must be balanced with regulation of their use so that resistance to the new drugs can be prevented. To foster the rational use of new drugs, we propose 1) expanding/strengthening the capacity for drug susceptibility testing, beginning with countries with a high TB burden; 2) regulating prescribing practices by banning over-the-counter sale of TB drugs and enacting an accreditation system whereby providers must be certified to prescribe new drugs; and 3) decentralizing MDR TB care in rural communities by employing trained community health workers, using promising mobile technologies, and enlisting the aid of civil society organizations.
2.Short-course treatment for multidrug-resistant tuberculosis: the STREAM trials.
Moodley R1, Godec TR2; STREAM Trial Team. Eur Respir Rev. 2016 Mar;25(139):29-35. doi: 10.1183/16000617.0080-2015.
Multidrug-resistant (MDR) tuberculosis (TB) is a threat to global TB control, as suboptimal and poorly tolerated treatment options have resulted in largely unfavourable outcomes for these patients. The last of six cohort studies conducted in Bangladesh which assessed a new shorter regimen using currently available TB drugs showed promising results and offered the possibility of a more acceptable and more effective regimen than the one recommended by the World Health Organization (WHO). The aims of stage 1 of the STREAM (Evaluation of a Standardised Treatment Regimen of Anti-tuberculosis Drugs for Patients with Multidrug-resistant Tuberculosis) trial are to evaluate the efficacy and safety of this regimen, compared to the current WHO-recommended standard of care. Stage 2 evaluates two new bedaquiline-containing regimens: one an all-oral regimen and the second a further shortened and simplified version of the stage 1 study regimen, comparing the efficacy and safety of each to that of the stage 1 study regimen and also to the WHO-recommended standard of care.
3.Preliminary Favorable Outcome for Medically and Surgically Managed Extensively Drug-Resistant Tuberculosis, France, 2009-2014.
Emerg Infect Dis. 2016 Mar;22(3). doi: 10.3201/eid2203.151130.
We report 20 cases of extensively drug-resistant tuberculosis managed in France. Treatment was individualized and included bedaquiline and linezolid for most patients and surgery in 8 patients. At last follow-up (22 months), 19 patients had achieved conversion from positive to negative on culture testing. These promising results of comprehensive management obtained in a small series deserve confirmation.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Antibacterial Products


CAS 42540-40-9 Cefamandole nafate

Cefamandole nafate
(CAS: 42540-40-9)

Cefamandole nafate is the formate ester cefamandole, as a broad-spectrum cephalosporin antibiotic

CAS 24356-60-3 Cephapirin Sodium

Cephapirin Sodium
(CAS: 24356-60-3)

Cephapirin is a cephalosporin antibiotic agent.

CAS 15176-29-1 Edoxudine

Edoxudine
(CAS: 15176-29-1)

Edoxudine, synthesised via organopalladium intermediates, is an antiviral drug.

CAS 119478-56-7 Meropenem trihydrate

Meropenem trihydrate
(CAS: 119478-56-7)

Meropenem (trihydrate) is a carbapenem antibiotic, which displaying a broad spectrum of antibacterial activity.

CAS 72558-82-8 Ceftazidime

Ceftazidime
(CAS: 72558-82-8)

Ceftazidime is an antibiotic useful for the treatment of a number of bacterial infections. It is a third-generation cephalosporin, but it is not used to treat v...

CAS 5490-27-7 Dihydrostreptomycin sesquisulfate

Dihydrostreptomycin sesquisulfate
(CAS: 5490-27-7)

Dihydrostreptomycin sesquisulfate is a derivative of Streptomycin used to treat bacterial diseases in cattle, pigs and sheep.

CAS 140896-21-5 Indolicidin

Indolicidin
(CAS: 140896-21-5)

Indolicidin is the smallest of the naturally known occurring linear antimicrobial peptides, containing the highest percentage of tryptophan of any known protein...

Alatrofloxacin Mesylate
(CAS: 157605-25-9)

The mesylate salt form of alatrofloxacin, a fluoroquinolone derivative, has been found to be a Type II DNA topoisomerase inhibitor that was once developed to be...

Chemical Structure

CAS 843663-66-1 Bedaquiline

Quick Inquiry

Verification code

Featured Items